Shiloh
Editor, Senior Moderator
Source: https://www.cidrap.umn.edu/news-perspective/2021/12/stewardship-resistance-scan-dec-15-2021
Stewardship / Resistance Scan for Dec 15, 2021
G7 on antibiotic development; Pneumonia antibiotics trial
Filed Under:
Antimicrobial Stewardship
G7 finance ministers commit to addressing antibiotic market failure
Finance ministers for G7 countries yesterday issued a statement in support of actions to boost development of new antibiotics.
Citing the lessons of the COVID-19 pandemic and the need to prepare for the long-term health and economic consequences of antimicrobial resistance (AMR), the G7 finance ministers committed to taking "additional and appropriate" steps to address the failure of the antibiotic market, create the right economic conditions to preserve essential antibiotics, strengthen antibiotic research and development, and bring new drugs to market where they meet identified public health needs.
The steps outlined include exploring a range of market incentive options, with a particular emphasis on "pull" incentives, new pilot projects, and legislative and regulatory measures.
"We are committed to strengthen and intensify our action across the G7," the statement said. "Recognising that this is a multiyear and multi-stakeholder effort, we ask our finance and health officials to work with relevant technical agencies, international organisations, industry, and investors to continue this dialogue and share best practice."
The statement also committed all G7 members to implementing their existing strategies to address AMR, as outlined in their national action plans.
Dec 14 G7 finance ministers' statement
Study will explore ways to limit broad-spectrum antibiotics for pneumonia
The Cleveland Clinic announced last week that it has received funding from the Agency of Healthcare Research and Quality (AHRQ) to conduct a clinical trial to evaluate ways to reduce and target use of broad-spectrum antibiotics for community-acquired pneumonia (CAP).
The $2.5 million from AHRQ will fund a multicenter, randomized clinical trial that will test two approaches to limiting broad-spectrum antibiotics in hospitalized adult CAP patients: routine use of rapid diagnostic testing at the time of hospital admission, and pharmacist-led antibiotic de-escalation.
Approximately 1 million US adults are hospitalized for pneumonia each year, and 50,000 die from it. Though pneumonia is caused by bacteria, viruses, and fungi, most patients aren't tested for the cause and are typically treated with antibiotics.
"Our overall goal is to improve antimicrobial prescribing for patients with community-acquired pneumonia," trial co-lead Abhishek Deshpande, MD, PhD, a staff physician with Cleveland Clinic's Center for Value-Based Research, said in a press release. "Specifically, knowledge gained from this trial will allow physicians to limit the use of broad-spectrum antimicrobials and initiate targeted therapy."
Dec 9 Cleveland Clinic press release
Stewardship / Resistance Scan for Dec 15, 2021
G7 on antibiotic development; Pneumonia antibiotics trial
Filed Under:
Antimicrobial Stewardship
G7 finance ministers commit to addressing antibiotic market failure
Finance ministers for G7 countries yesterday issued a statement in support of actions to boost development of new antibiotics.
Citing the lessons of the COVID-19 pandemic and the need to prepare for the long-term health and economic consequences of antimicrobial resistance (AMR), the G7 finance ministers committed to taking "additional and appropriate" steps to address the failure of the antibiotic market, create the right economic conditions to preserve essential antibiotics, strengthen antibiotic research and development, and bring new drugs to market where they meet identified public health needs.
The steps outlined include exploring a range of market incentive options, with a particular emphasis on "pull" incentives, new pilot projects, and legislative and regulatory measures.
"We are committed to strengthen and intensify our action across the G7," the statement said. "Recognising that this is a multiyear and multi-stakeholder effort, we ask our finance and health officials to work with relevant technical agencies, international organisations, industry, and investors to continue this dialogue and share best practice."
The statement also committed all G7 members to implementing their existing strategies to address AMR, as outlined in their national action plans.
Dec 14 G7 finance ministers' statement
Study will explore ways to limit broad-spectrum antibiotics for pneumonia
The Cleveland Clinic announced last week that it has received funding from the Agency of Healthcare Research and Quality (AHRQ) to conduct a clinical trial to evaluate ways to reduce and target use of broad-spectrum antibiotics for community-acquired pneumonia (CAP).
The $2.5 million from AHRQ will fund a multicenter, randomized clinical trial that will test two approaches to limiting broad-spectrum antibiotics in hospitalized adult CAP patients: routine use of rapid diagnostic testing at the time of hospital admission, and pharmacist-led antibiotic de-escalation.
Approximately 1 million US adults are hospitalized for pneumonia each year, and 50,000 die from it. Though pneumonia is caused by bacteria, viruses, and fungi, most patients aren't tested for the cause and are typically treated with antibiotics.
"Our overall goal is to improve antimicrobial prescribing for patients with community-acquired pneumonia," trial co-lead Abhishek Deshpande, MD, PhD, a staff physician with Cleveland Clinic's Center for Value-Based Research, said in a press release. "Specifically, knowledge gained from this trial will allow physicians to limit the use of broad-spectrum antimicrobials and initiate targeted therapy."
Dec 9 Cleveland Clinic press release